Abstract
CD40 is a member of the TNF family of receptors that has been shown to play a crucial role in enhancing dendritic cell activity and fostering anti-tumor immune responses. In this study, we demonstrate the in vitro properties and in vivo efficacious activity of the CD40 agonist antibody, CP-870,893. CP-870,893 is a fully human, IgG2 antibody that selectively interacts with CD40 at a site distinct from its ligand-binding region with a KD of 0.4 nM. It enhances the expression of MHC class II, CD54, CD86, and CD23 on human B cells in vitro. CP-870,893 also enhances dendritic cell activity as evidenced by cytokine secretion (IL-12, IL-23, IL-8), the upregulation of CD86 and CD83, and the ability to prime T cells to secrete IFNγ. In SCID-beige mice, a single parenteral injection of CP-870,893 was therapeutically effective against several CD40pos human tumors (B-cell lymphoma, breast, colon, and prostate) indicating direct effects on tumor cell survival and/or growth. When mice were co-implanted with human T cells and dendritic cells, the activity of CP-870,893 against CD40pos tumors increased, and efficacy was also observed against CD40neg and CD40low tumors demonstrating the ability of CP-870,893 to enhance anti-tumor immune function in vivo. These studies suggest that CP-870,893 has the potential to be efficacious against a wide range of tumor types through both direct and immune-mediated effects.
Similar content being viewed by others
References
Chaudhuri D, Suriano R, Mittelman A, Tiwari RK (2009) Targeting the immune system in cancer. Curr Pharm Biotechnol 10:166–184
Lustgarten J (2009) Cancer, aging and immunotherapy: lessons learned from animal models. Cancer Immunol Immunother 58:1979–1989
Elgueta R, Benson MJ, de Vries VC, Wasiuk A, Guo Y, Noelle RJ (2009) Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol Rev 229:152–172
Diehl L, Den Boer AT, van der Voort EI, Melief CJ, Offringa R, Toes RE (2000) The role of CD40 in peripheral T cell tolerance and immunity. J Mol Med 78:363–371
Sartorius R, D’Apice L, Barba P et al (2003) Induction of human NK cell-mediated cytotoxicity by CD40 triggering on antigen presenting cells. Cell Immunol 221:81–88
Davis ID, Chen Q, Morris L et al (2006) Blood dendritic cells generated with Flt3 ligand and CD40 ligand prime CD8+ T cells efficiently in cancer patients. J Immunother 29:499–511
Mackey MF, Gunn JR, Ting PP et al (1997) Protective immunity induced by tumor vaccines requires interaction between CD40 and its ligand, CD154. Cancer Res 57:2569–2574
Hanyu K, Iida T, Shiba H, Ohashi T, Eto Y, Yanaga K (2008) Immunogene therapy by adenovirus vector expressing CD40 ligand for metastatic liver cancer in rats. Anticancer Res 28:2785–2789
Dzojic H, Loskog A, Totterman TH, Essand M (2006) Adenovirus-mediated CD40 ligand therapy induces tumor cell apoptosis and systemic immunity in the TRAMP-C2 mouse prostate cancer model. Prostate 66:831–838
French RR, Chan HT, Tutt AL, Glennie MJ (1999) CD40 antibody evokes a cytotoxic T cell response that eradicates lymphoma and bypasses T cell help. Nat Med 5:548–553
French RR, Taraban VY, Crowther GR et al (2007) Eradication of lymphoma by CD8 T cells following anti-CD40 monoclonal antibody therapy is critically dependent on CD27 costimulation. Blood 109:4810–4815
Honeychurch J, Glennie MJ, Johnson PW, Illidge TM (2003) Anti-CD40 monoclonal antibody therapy in combination with irradiation results in a CD8 T cell-dependent immunity–B cell lymphoma. Blood 102:1449–1457
Tutt AL, O’Brien L, Hussain A, Crowther GR, French RR, Glennie MJ (2002) T cell immunity to lymphoma following treatment with anti-CD40 monoclonal antibody. J Immunol 168:2720–2728
Todryk SM, Tutt AL, Green MH et al (2001) CD40 ligation for immunotherapy of solid tumours. J Immunol Methods 248:139–147
van Mierlo GJ, den Boer AT, Medema JP et al (2002) CD40 stimulation leads to effective therapy of CD40(−) tumors through induction of strong systemic cytotoxic T lymphocyte immunity. Proc Natl Acad Sci USA 99:5561–5566
Diehl L, den Boer AT, Schoenberger SP et al (1999) CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nat Med 5:774–779
Vonderheide RH, Dutcher JP, Anderson JE et al (2001) Phase I study of recombinant human CD40 ligand in cancer patients. J Clin Oncol 19:3280–3287
Toes RE, Schoenberger SP, van der Voort EI, Offringa R, Melief CJ (1998) CD40-CD40 ligand interactions and their role in cytotoxic T lymphocyte priming and anti-tumor immunity. Semin Immunol 10:443–448
Hirano A, Longo DL, Taub DD et al (1999) Inhibition of human breast carcinoma growth by a soluble recombinant human CD40 ligand. Blood 93:2999–3007
Hill SC, Youde SJ, Man S et al (2005) Activation of CD40 in cervical carcinoma cells facilitates CTL responses and augments chemotherapy-induced apoptosis. J Immunol 174:41–50
Gomes EM, Rodrigues MS, Phadke AP et al (2009) Antitumor activity of an oncolytic adenoviral-CD40 ligand (CD154) transgene construct in human breast cancer cells. Clin Cancer Res 15:1317–1325
Georgopoulos NT, Merrick A, Scott N, Selby PJ, Melcher A, Trejdosiewicz LK (2007) CD40-mediated death and cytokine secretion in colorectal cancer: a potential target for inflammatory tumour cell killing. Int J Cancer 121:1373–1381
Vonderheide RH, Butler MO, Liu JF et al (2001) CD40 activation of carcinoma cells increases expression of adhesion and major histocompatibility molecules but fails to induce either CD80/86 expression or T cell alloreactivity. Int J Oncol 19:791–798
Frucht DM (2002) IL-23: a cytokine that acts on memory T cells. Sci STKE 114:1–3
Tahara H, Lotze MT (1995) Antitumor effects of interleukin-12 (IL-12): applications for the immunotherapy and gene therapy of cancer. Gene Ther 2:96–106
Tsung K, Meko JB, Peplinski GR, Tsung YL, Norton JA (1997) IL-12 induces T helper 1-directed antitumor response. J Immunol 158:3359–3365
Weerasekera N, Hudson I (2007) Lessons from TGN-1412: the impact on phase I clinical trials. IDrugs 10:230–232
Biancone L, Cantaluppi V, Boccellino M et al (1999) Activation of CD40 favors the growth and vascularization of Kaposi’s sarcoma. J Immunol 163:6201–6208
Vonderheide RH, Flaherty KT, Khalil M et al (2007) Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol 25:876–883
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gladue, R.P., Paradis, T., Cole, S.H. et al. The CD40 agonist antibody CP-870,893 enhances dendritic cell and B-cell activity and promotes anti-tumor efficacy in SCID-hu mice. Cancer Immunol Immunother 60, 1009–1017 (2011). https://doi.org/10.1007/s00262-011-1014-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00262-011-1014-6